BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant Abbott Laboratories Limited submitted on 27 June 2000  an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Kaletra, 
through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21  December  1999,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Eric Abadie 
Co-Rapporteur:  Dr. Jean-Louis Robert 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. Kaletra was 
granted a license in the United States on 15 September 2000. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 July 2000. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 29 September 
2000. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 26 
September 2000. 
The summary report of the inspection carried out at the manufacturing site RP Scherer between 
31 July-3 August 2000 by the Medicines Control Agency, was issued on 19 September 2000. 
During  the  meeting  on  14-16  November  2000,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
The  CPMP  agreed  on  the  consolidated  list  of  questions  to  be  sent  to  the  applicant.  The  final 
consolidated list of questions was sent to the applicant on 16 November 2000. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  24 
November 2000. 
The Rapporteur circulated the joint assessment report on the applicant’s responses to the list of 
questions to all CPMP Members on 4 December 2000. 
The  Rapporteur  circulated  an  assessment  report  on  the  Purkinje  Fibers  study  to  all  CPMP 
Members on 11 December 2000. 
During  the  meeting  on  12-14  December  2000,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  Kaletra  soft  capsules 
and oral solution on 14 December 2000. The applicant provided a letter of undertaking of the 
specific obligations and follow-up measures to be fulfilled post-authorisation on 13 December 
2000. 
The EMEA forwarded the opinion to the European Commission who issued on 20 March 2001 
the respective Decision for granting a Marketing Authorisation under exceptional circumstances 
to Kaletra soft capsules and oral solution. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
